Purpose The purpose of this study was to evaluate baseline RRM2 protein and gene expression in tumors of patients receiving 3-AP. Methods Tumor blocks from patients enrolled in phase I and II clinical studies using 3-AP, were evaluated for RRM2 gene and protein expression by quantitative real time polymerase chain reaction (Q-RTPCR) and automated quantitative analysis (AQUA). Results Esophageal and gastric cancers overexpressed RRM2 protein when compared to prostate cancer (Z-score, 0.68 § 0.94 SD, vs 0.41 § 0.84 SD, respectively; p = 0.04). Esophageal and gastric cancers also overexpressed RRM2 mRNA when compared to prostate cancer (relative gene expression 2.56 § 1.49 SD, vs 0.29 § 0.20 SD, respectively; p = 0.02). Protein and gene expression were moderately associated (Spearman's rank correlation = 0.30; p = 0.12). Conclusion RRM2 gene and protein expression varies by tumor type.
Introduction
Ribonucleotide reductase (RR) is the enzyme that catalyzes the conversion of ribonucleoside 5Ј-diphosphates into 2Ј-deoxyribonucleotides [1] . RR consists of one regulatory subunit, RRM1, and one catalytic subunit, RRM2. Together, RRM1 and RRM2 form the catalytically active RR enzyme. RRM1 has binding sites for ribonucleotides, and its expression in proliferating cells remains consistent throughout the cell cycle. RRM2 contains a tyrosyl-free radical that is stabilized by a non-heme iron center, which is essential for ribonucleotide reduction and conversion of nucleotides to deoxynucleotides [2] . This conversion is a rate-limiting step in the production of 2Ј-deoxyribonucleoside 5Ј-triphosphates that are necessary for DNA replication, making RRM2 essential in DNA synthesis.
Overexpression of RR2M is associated with increased cell proliferation [3] and malignant potential in certain cancers and inhibition of RRM2 reduces cellular proliferation in vitro and in vivo [4, 5] . RRM2 interacts with a variety of oncogenes which promotes tumor progression [6, 7] , enhances the invasiveness of cancer cells [8] , reduces radiosensitivity in human solid tumors [9] and increases the drug-resistant properties of cancer cells to various chemotherapeutic reagents, including hydroxyurea and gemcitabine [10] [11] [12] [13] . Therefore, inhibition of RRM2 is a potential therapeutic target for new anti-cancer agents. Triapine ® (3-aminopyridine-2-carboxaldehyde thiosemicarbazone, 3-AP, Vion Pharmaceuticals, Inc., New Haven, CT, USA), is a novel small molecule inhibitor of RRM2 that is being evaluated in Phase I and II clinical trials. In this study, we hypothesized that baseline tumor RRM2 expression varies by tumor and RRM2 expression may be used to identify tumors sensitive to 3-AP.
Materials and methods
Formalin-Wxed paraYn-embedded (FFPE) tissue blocks were obtained from 40 of the 43 patients with locally advanced, unresectable or metastatic solid tumors who participated in three clinical trials at the University of Wisconsin. The trials were a phase I combination of 3-AP and doxorubicin [14] , a phase I combination of 3-AP and irinotecan [15] and a phase II single agent study of 3-AP in pancreatic cancer [16] . There were 13 tissue blocks from patients with pancreatic cancer (four from primary sites and nine from metastatic sites). Other tissue types included: one primary bladder cancer; one primary cervical cancer; four cholangiocarcinoma (one primary, three metastatic); two primary colon cancers; three primary esophageal cancers, one primary gastric cancer, one metastatic lymphoma, three primary melanomas, two primary mesotheliomas, one primary non-small cell lung cancer (NSCLC), two primary prostate cancers, one primary sarcoma and one primary small cell lung cancer (SCLC). All samples were available for automated quantitative immunohistochemistry (AQUA) analysis. Seven individuals with pancreas cancer, two with breast cancer and one with lymphoma did not have suYcient material for RNA analysis. The Health Sciences Institutional Review Board of the University of Wisconsin approved these trials prior to their implementation, and all patients gave informed written consent.
Laser capture microdissection
Sections were prepared from each FFPE tissue blocks, and hematoxylin and eosin (H&E) staining was performed. H&E stained slides were reviewed by a pathologist to determine the location of tumor tissue on each slide. Laser capture microdissection (LCM) with the SL Cut Laser Microdissection System (Molecular Machines and Industries, Glattbrug, Switzerland) was utilized to ensure the isolation of only tumor cells. BrieXy, the sections were melted at 60°C for 30 min and deparaYnized in xylene. Sections were then rehydrated in graded ethanol, rinsed with DEPCtreated water, stained with toluidine blue, rinsed in DEPCtreated water, dehydrated in graded ethanol followed by isopropanol and placed in a desiccator until dry. A minimum of 1,000 tumor cells were collected. The cells were Wxed to 500 L tube with adhesive lid (Molecular Machines and Industries AG, Rockledge, FL, USA) using MMI CellCut (Molecular Machines and Industries AG, Rockledge, FL, USA) LCM system in combination with a Nikon Eclipse TE2000-S microscope (Nikon Inc., Melville, NY, USA). After LCM, RNA extraction was performed using the Paradise Whole Transcript RT Reagent System (Arcturus Bioscience, Sunnyvale, CA, USA) which processes FFPE tissue scrapes. Caps were placed in a microcentrifuge tubecontaining proteinase K and incubated at 37°C for 16-20 h. After centrifugation, the caps were removed and the RNA was isolated and treated with DNAase following the manufacture's instructions. The total RNA was resuspended and then treated with DNase. Total RNA was stored at ¡80°C until analyzed. The RNA was quantiWed via NanoDrop ND-1000 (NanoDrop Technologies, Wilmington, DE, USA), and the total RNA extracted from FFPE tumor tissue was reverse transcribed using random primers by standard methods. All samples had a 260 nm/280 nm ratio >1.5 and the mean RNA concentration was 611 ng/ L.
TaqMan assays were designed for the genes listed in Table 1 with primers designed (Integrated DNA Technologies, Coralville, IA, USA) to keep the amplicon length <100 bp. Quantitative real time PCR was performed using the Bio-Rad iCycler IQ system (Hercules, CA, USA). Due to the limited sample supply, the target gene (RRM2) and the endogenous reference gene (YWHAZ) were ampliWed in a single well. Each well contained 5 pmol/ L of the probes, 5 pmol/ L of the primers, and 12.5 L of iQ Multiplex Powermix (Bio-Rad, Hercules, CA, USA) in a 25 L Wnal reaction mixture. The Multiplex Powermix was heatactivated for 3 min at 95°C. Each of the 50 PCR cycles consisted of 15 s of denaturation at 95°C and hybridization of primers and probes for 45 s at 60°C.
Expression levels in the patient samples were determined by the standard curve method using standard cDNA solutions which were serially diluted Wvefold from the HepG2 carcinoma cell line. The standard curve and sam-ples were run in triplicate, and nontemplate controls were included in each run. The data was analyzed with the standard curve line equations generated by iQ5 software (BioRad). The starting mass value for the gene of interest and reference gene were calculated by substituting the threshold cycle (Ct) values generated by the iQ5 software into the standard curve formula. The Ct (threshold cycle) is deWned as the fractional cycle number at which the Xuorescence passes the Wxed threshold. The data was expressed as target gene (RRM2)/endogenous gene (YWHAZ). The correlation coeYcient (r) for each standard curve exceeded 0.99, and the coeYcient of variation for the Ct values was less than 3.5% for all replicates.
Standards were included on every plate run. If any of the Ct values for the subject samples fell outside the range of the standard curve the samples were diluted and were rerun. RRM2 standard curve Ct values averaged 28.6 for 400 ng and 39.9 for 0.128 ng. YWHAZ standard curve Ct values averaged 26.1 for 400 ng and 37.6 for 0.128 ng. The average subject sample Ct values for RRM2 and YWHAZ were 36.0 (range 29.3-41.8) and 32.3 (range 26.0-38.7), respectively. Three out of 36 subject samples had RRM2 Ct values ¸40 (40.1, 40.2, and 41.8). None of the YWHAZ Ct values were ¸40. All the data came from runs that had negative no template controls.
Validation summary
Linearity was determined with Wve standard curves, and the mean coeYcient of determination (r2) for RRM2 was 0.990 (range 0.982-0.998) and for YWHAZ was 0.996 (range 0.994-0.998). Triplicate determinations of each standard were run on a single plate on Wve separate occasions over a two-week period. The intra-day variability in the standard Ct readings for RRM2 averaged 0.65% (range 0.09-2.84%), while for YWHAZ the standard Ct readings averaged 0.61% (range 0.06-1.96%). The mean CV in the Ct values for RRM2 over this time ranged from 0.32% (range 0.09-0.68%) for the 400 ng standard to 1.47% (range 0.66-2.84%) for the 0.128 ng standard. For YWHAZ, the mean CV in the Ct values over the standard curve ranged from 0.54% (range 0.31-1.03%) for the 400 ng standard to 1.11% (0.33-1.96%) for the 0.128 ng standard. Triplicate determinations of Ct readings in Wve patient samples on a single plate had a mean CV for RRM2 of 1.18% (range 0.25-2.21%) over the mass range of 0.19-114.43 ng (all samples were diluted). In the same Wve patient samples, the mean CV for YWHAZ was 0.70% (range 0.03-1.14%) over the mass range of 0.13-116.12 ng (all samples were diluted). The variability did not change with concentration.
M2 protein analysis by automated quantitative analysis (AQUA)
RRM2 expression was determined using the AQUA system (HistoRx, New Haven, CT, USA) as previously described [17] [18] [19] . Initially, target compartments were localized using a Xuorescently tagged rabbit anti-cytokeratin antibody (or the anti-S100 antibody for melanoma cells). 4,6-Diamidino-2-phenylindole (DAPI) was added to visualize nuclei. RRM2 was visualized with an Alexa Fluor 488 labeled tyramide which, like diaminobenzidine, is activated by horseradish peroxidase and results in the deposition of numerous covalently associated Alexa Fluor 488 dyes immediately adjacent to the horseradish peroxidase-conjugated secondary antibody (Fig. 1) . Residual clinical specimens were utilized as positive and negative controls. Negative controls were incubated without antibody. NonspeciWc staining was rules out by use of negative controls. Using this approach, classical compartments are deWned on the basis of molecular co-localization. The cytokeratin compartment is equivalent to all epithelial cells in the tissue section. The S-100 compartment is equivalent to melanoma cells in tissue section. DAPI is the area deWned as the cell nucleus. A matched set of H&E sections were used for locating tumor. Multiple monochromatic, high-resolution (2,048 £ 2,048 pixel, 7.4-m) 8-bit grayscale images were obtained for each selected area of interest to quantify signal intensity using the 20£ objective of an Olympus BX-51 epiXuorescence microscope (Olympus, Melville, NY, USA) with an automated microscope stage and digital image acquisition driven by a custom program and macrobased interfaces with HistoRx AQUA software (New Haven, CT, USA). RRM2 signal was measured within the subcellular compartments by the PLACE algorithm as previously described: brieXy, two images (one in-focus and one out-offocus) were taken of the compartment speciWc tags and the target marker. An algorithm described as rapid exponential subtraction algorithm (RESA) was used to subtract the outof-focus information in a uniform fashion for the entire selected area of interest. Subsequently, the PLACE was used to assign each pixel in the image to a speciWc subcellular compartment and the signal in each location is calculated. Pixels that cannot accurately be assigned to a compartment were discarded. The data were saved and subsequently expressed as the average signal intensity per unit of compartment area. All the signals in each compartment were then added. The AQUA score was expressed as target signal intensity divided by the compartment pixel area and was expressed on a scale of 0 to 33333 (AQUA_1.5, HistoRx). The resultant AQUA score is directly proportional to the number of molecules per unit area. Since the slides were stained through several experiments, to ensure the signal intensities in diVerent experiments are comparable, data is represented as a Z-score, which was calculated by subtracting the mean AQUA score from the individual AQUA score and dividing by the standard deviation [18, 19] . Therefore a negative Z-score indicates the protein expression was less than the average and a positive Z-score means it is greater than the average.
Statistical methods
RRM2 gene expression and protein expression were summarized in terms of number of observations, means and standard deviations. The data were presented in graphical format using boxplots. The comparisons between groups were performed using a non-parametric Wilcoxon Rank Sum test or the Kruskal-Wallis test. Exact p values were computed for all comparisons. All statistical tests were two-sided, and p < 0.05 was used to indicate statistical signiWcance. Due to the exploratory nature of this study, no adjustments for multiple comparisons were made. Fig. 1 Protein expression of ribonucleotide reductase M2 (RRM2) was determined using an automated in situ quantitative measurement of protein analysis, automated quantitative immunohistochemistry on the basis of immunoXuorescence. A prostate cancer specimen is displayed in this Wgure. a Target compartments were localized using a Xuorescently tagged Alexa Fluor 555, rabbit anti-cytokeratin antibody (green). b 4,6-Diamidino-2-phenylindole was added to visualize nuclei (blue). c RRM2 was visualized with Alexa Fluor 488-tyramide, human anti-RRM2 (red). d A three color overlay shows localization of RRM2 to the cytoplasm Non-parametric Spearman's rank correlation analysis was used to examine the association between protein and gene expression levels. Statistical analysis was performed using SAS ® (SAS Institute Inc., Cary, North Carolina, USA) version 9.1 software.
Results

RRM2 expression by tumor type
AQUA demonstrated that RRM2 protein localized to the cytoplasm (Fig. 1) , where it is produced. Table 2 lists the number and types of samples that were analyzed. Comparisons were made for tumor types where at least three tissue blocks were available. The median Z-scores were as follows: pancreatic cancers (n = 13) ¡0.41 § 0.84, for cholangiocarcinoma (n = 4) ¡0.21 § 0.23, for esophageal and gastric cancers (n = 4) 0.68 § 0.95, and for melanoma (n = 3) it 0.74 § 0.57. The p value for the comparison across all four tumor types is 0.03 (Kruskal-Wallis test), suggesting that at least one tumor type is diVerent than the others (Fig. 2) . Pairwise comparisons between the groups with the Wilcoxan Rank Sum test demonstrate cholangiocarcinoma and esophageal cancer are signiWcantly diVerent (p = 0.03), pancreatic cancer and esophageal/gastric cancer are signiWcantly diVerent (p = 0.04), and that pancreatic cancer and melanoma show a trend towards diVerence (p = 0.06).
The RRM2 gene expression relative to the housekeeping gene YWHAZ for pancreatic cancers (n = 6) was 0.29 § 0.20, for cholangiocarcinoma (n = 4) was 0.54 § 0.52, for esophageal/gastric cancers (n = 4) 2.56 § 1.49, and for melanoma (n = 3) it was 0.79 § 0.22. The p value for the comparison across all four tumor types is 0.03 (Wilcoxon Rank Sum test), suggesting that at least one tumor type is diVerent than the others. See Fig. 3 . Pairwise comparisons between the groups with the Kruskal-Wallis test demonstrate that pancreas cancer and esophageal/gastric cancer (p = 0.02), and prostate cancer and melanoma (p = 0.05) are signiWcantly diVerent. Cholangiocarcinoma and esophageal cancers show a trend towards diVerence (p = 0.06).
Spearman's rank correlation analysis was performed to examine the association between RRM2 protein expression as evaluated by AQUA and gene expression evaluated by Q-RTPCR in baseline tumor specimens. This analysis demonstrated a moderate correlation (Spearman's rank correlation = 0.30, p = 0.12) between the cancers, and two tumor types (SCLC and sarcoma) had highly discordant results (Table 2) .
Patient response
Two patients (5%) achieved a partial response by response evaluation criteria in solid tumors (RECIST) [20] . One patient with NSCLC, who received 3-AP at 85 mg/m 2 on days 1-3 of a 21 day cycle and irinotecan 150 mg/m 2 on day 1 of a 21 day cycle had a Z-score of 0.78 and a relative gene expression value of 2.43. Another patient with bladder cancer, who received 3-AP at 25 mg/m 2 days 1-4 of a 21 day cycle and doxorubicin at 60 mg/m 2 , on day 1 of a 21 day cycle had an unconWrmed PR and a Z-score of 0.57 and relative gene expression value of 2.17. While response rates were too low to perform a statistical analysis comparing responders to non-responders, both patients achieving a partial response had relatively high expression levels compared to other patients without a response (Table 2) .
Discussion
In this study, we evaluated diVerences in RRM2 mRNA and protein expression in baseline tumor samples. Our
Wndings demonstrated that RRM2 levels are higher in esophageal/gastric cancer and melanomas when compared to pancreatic cancer. Additionally, esophageal cancers have more expression when compared to cholangiocarcinomas. These diVerences in RRM2 were signiWcant despite small sample sizes and suggest that relative RRM2 overexpression may play a role in tumor development of esophageal and gastric cancers and melanoma, although conWrmatory studies are required. As RRM2 is the intracellular target of 3-AP, one potential application would be to evaluate RRM2 expression to predict 3-AP-sensitive tumors. Juhasz et al. [21] recently reported preliminary Wndings suggesting inhibition of RRM2 gene expression was associated with clinical response to the antisense agent GTI-2040 targeting RRM2. Two phase II trials of 3-AP have recently been reported [22, 23] with disappointing results. In a trial of single agent 3-AP in advanced renal cell cancer, Knox et al. [22] demonstrated a 7% (1/19) partial response rate. Mackenzie et al.
[23] studied 3-AP in combination with gemcitabine for advanced pancreatic cancer with no responses observed. While RRM2 expression was not evaluated, the clinical results are consistent with our own phase II trial of 3-AP in advanced pancreas cancer where no responses were observed [16] . Since RRM2 gene expression and protein expression in pancreas cancer was found to be signiWcantly less than in other solid tumors, low RRM2 expression may be a potential mechanism of 3-AP resistance.
While a statistical analysis could not be performed due to a limited sample size, both patients with a partial response had high RRM2 mRNA and protein levels. Since both patients achieving a partial response received chemotherapy in addition to 3-AP, the observed responses cannot be attributed solely to 3-AP relatively high baseline RRM2 expression. The patient with NSCLC received concurrent 3-AP and irinotecan, and the patient with bladder cancer received 3-AP and doxorubicin. However, given the single agent response rate of second-line irinotecan in metastatic NSCLC is less than 5% [24] and the single agent response rate for doxorubicin in bladder cancer is 17% [25] , our data suggest that increased baseline expression of RRM2 and 3-AP may contribute to the activity of the regimen. In this analysis, protein expression and mRNA expression were moderately correlated. This association can likely be explained by the SCLC and sarcomas that had highly discordant results. The data suggest that for the majority of tumors, transcription is an important mechanism controlling RRM2 protein expression. In some tumors, however, transcription and expression do not appear to be linked, and unknown mechanisms may control protein expression. This analysis also raises an important question regarding the preferred method for expression analysis, which cannot be answered in the current study. Further studies comparing protein expression to mRNA expression to 3-AP response and mechanistic studies to determine the relationship between mRNA expression and protein expression for RRM2 are necessary.
In conclusion, both RRM2 gene and protein expression vary by tumor type in baseline tumor samples. Given the poor phase II activity of 3-AP in renal cell and pancreatic cancer, one potential application of our Wndings would be evaluating baseline RRM2 to predict tumors sensitive to 3-AP.
